Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Glibenclamide treatment in permanent neonatal diabetes mellitus due to an activating mutation in Kir6.2.

The Journal of clinical endocrinology and metabolism - 1 Nov 2004

Zung Amnon, Glaser Benjamin, Nimri Revital, Zadik Zvi

Abstract excerpt

Permanent neonatal diabetes mellitus (PNDM) is a rare form of diabetes characterized by insulin-requiring hyperglycemia that is diagnosed within the first months of life. Recently, activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 were identified in 10 PNDM patients. Tolbutamide-stimulated insulin secretion, demonstrated in 3 of these patients suggested that some PNDM...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Blood Glucose
Share to Diabetes Mellitus

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glyburide

Share to Hypoglycemic Agents

Share to Mutation

Share to Potassium Channels, Inwardly Rectifying

Source

Identifiers

PMID: 15531505
DOI: 10.1210/jc.2004-1241

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Glibenclamide treatment in permanent neonatal diabetes mellitus due to an activating mutation in Kir6.2.PMID 15531505Read ↗

Familial permanent neonatal diabetes with KCNJ11 mutation and the response to glyburide therapy--a three-year follow-up.Semantic proximity Read ↗

Permanent Neonatal Diabetes due to Mutations in <i>KCNJ11</i> Encoding Kir6.2Semantic proximity Read ↗

Sulfonylurea therapy in two Korean patients with insulin-treated neonatal diabetes due to heterozygous mutations of the KCNJ11 gene encoding Kir6.2.Semantic proximity Read ↗

Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes.Semantic proximity Read ↗

Outpatient transition of an infant with permanent neonatal diabetes due to a KCNJ11 activating mutation from subcutaneous insulin to oral glyburide.Semantic proximity Read ↗

Kir6.2 Mutations Are a Common Cause of Permanent Neonatal Diabetes in a Large Cohort of French PatientsSemantic proximity Read ↗

Successful transfer from insulin to oral sulfonylurea in a 3-year-old girl with a mutation in the KCNJ11 gene.Semantic proximity Read ↗

Diabetes and hypoglycaemia in young children and mutations in the Kir6.2 subunit of the potassium channel: therapeutic consequences.Semantic proximity Read ↗

Early Postnatal Use of Glibenclamide in Permanent Neonatal Diabetes Secondary to Antenatally Diagnosed KJCN11 Mutation.Semantic proximity Read ↗

Permanent neonatal diabetes by a new mutation in KCNJ11: unsuccessful switch to sulfonylurea.Semantic proximity Read ↗

Mutations in the Kir6.2 subunit of the KATP channel and permanent neonatal diabetes: new insights and new treatment.Semantic proximity Read ↗

Activating mutations in Kir6.2 and neonatal diabetes: new clinical syndromes, new scientific insights, and new therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.